September 25, 2020

Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings

Category: Article Summary

Topic: Testing and Treatment

Keywords (Tags): testing

• [Pre-print, not peer reviewed] A comparison of ten commercial serological tests for SARS-CoV-2 antibodies found sensitivity ranging from 61% to 87% and specificity ranging from 82% to 100% when compared to an in-house ELISA. The in-house test was selected as the reference test because there is no accepted “gold standard” for the detection of SARS-CoV2 antibodies. Across tests, the likelihood of detecting antibodies was highest in samples collected 20 days after symptom onset.

Pickering et al. (Sept 25, 2020). Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings. Pre-print downloaded Sept 25 from https://doi.org/10.1101/2020.06.02.20120345